Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
Microbix has signed a Letter of Intent with Zydus Cadila, a global pharmaceutical company headquartered in India, to market the thrombolytic drug Urokinase in North American markets. According to Microbix, the estimated market size for Urokinase in the USA alone is expected to be about $400 million by 2020. This is a good start towards restoring investor confidence in MBX, but much remains to be done.
For more detail on this development and to read our January 5th report on the Company’s 2011 fiscal results, click here: Microbix_Biosystems_Perspectives
eResearch posts all its reports and articles on its website, www.eresearch.ca, and subscription is FREE.
eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.
eResearch: Bob Weir, CFA, Managing Director, Research Services